US/UK/Canada

Share

Contacts

  • Cyxone AB
    Hyllie Boulevard 34, 215 32 Malmö, Sweden
    +46 708882172
    +46 708882172
    http://www.cyxone.com

    • Quotes

    We are happy to announce the positive study outcomes, an instrumental part of the preparations for the Phase 2 study in RA patients set to start late next year. Equally, we are eagerly looking forward to the imminent initiation of our clinical study of Rabeximod in Covid-19 patients. Combined with the new patent applications recently filed, with potential to substantially prolong market exclusivity, and with a stockpile of drug substance enabling further clinical studies beyond those currently in the pipeline, we stand with a strong foothold in future partnering negotiations. All in all, Cyxone is well-positioned for the development of safe and innovative treatments toward serious immune system disorders.
    Tara Heitner, CEO, Cyxone
    After thorough evaluation, we were able to decide upon this CRO as our partner of choice for these preclinical studies. The selected CRO has an excellent reputation and we got a great impression of their quality and professionalism from the start. We now look forward to take the next step in the development program for our Phase II candidate Rabeximod.
    Malin Berthold, Head of Project Management at Cyxone
    This market maker is now being implemented to increase liquidity of our stock, which has sometimes been low. We look very favorably on this support measure, which is primarily done to benefit our shareholders through reduced trading risks.
    Kjell G. Stenberg, CEO of Cyxone
    The acquisition of Rabeximod is the most important milestone since Cyxone was founded. I have been following Rabeximod's development in OxyPharma for a long time and believe that this investment is very beneficial for our shareholders. We have in a short time been able to build a world-class autoimmune product portfolio, which has permeated the discussions we have had with different stakeholders regarding the financing of Rabeximod's phase IIb study. This is why we are now taking the opportunity to complete the payment and hope to return soon to our shareholders with more positive news regarding Rabeximod.
    Kjell G. Stenberg, CEO of Cyxone
    Pick a time period -

    Cyxone receives Intention to Grant from the European Patent Office for the divisional patent of T20K

    Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that the European Patent Office has issued an intention to grant communication for EP-Divisional Patent Application 18 172 126.7 entitled Cyclotides as immunosuppressive agents. The application covers the protection of the drug candidate T20K that Cyxone licenses from the Medical University of Vienna and the University of Freiburg.The intention to grant is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as

    Bulletin from the annual general meeting in Cyxone AB on 30 May 2023

    The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Today, on 30 May 2023, the annual general meeting was held in Cyxone AB. A summary of the adopted resolutions follows below.Resolution on adoption of accounts and allocation of the company’s result The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet. The annual general meeting also resolved in accordance with the

    Cyxone receives patent approval from the US for the salt forms of the compound rabeximod

    Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that the company has obtained granted status for the US patent application 17/891,462 entitled Rabeximod Compounds from the United States Patent and Trademark Office (USPTO).The application covers the protection of salt forms of the compound rabeximod which is being developed as treatment for moderate to severe rheumatoid arthritis. The patent will be valid until 2042. ”We are delighted to receive the final approval for this important patent. It is an essential fundament for the future development and

    Notice of annual general meeting in Cyxone AB

    The English text is an unofficial translation. In case of any discrepancies between the Swedish language version of this document and the English translation, the Swedish language version shall prevail. The shareholders in Cyxone AB, Reg. No. 559020-5471 (“Cyxone”), are hereby invited to the annual general meeting on Tuesday 30 May 2023 at 10.00 CEST, at the company’s office, Hyllie Stationstorg 31 in Malmö, Sweden.Right to participate and notification Shareholders wishing to attend the annual general meeting must: · be registered in the company’s share register kept by Euroclear

    Bulletin from the extraordinary general meeting in Cyxone AB on 18 April 2023

    The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Today, on 18 April 2023, an extraordinary general meeting was held in Cyxone AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority.The extraordinary general meeting resolved, in accordance with the proposal from the Nomination Committee, that the board of directors shall compose of three board members for the time until the close of the next annual general meeting. It

    BioStock: Cyxone’s CEO comments on the US patent notice

    Biotech company Cyxone develops new therapies for the treatment of autoimmune diseases, such as rheumatoid arthritis with the phase IIb candidate Rabeximod. The company reached a milestone in receiving a Notice of Allowance for the US patent of Rabeximod compounds. BioStock contacted CEO Carl-Magnus Högerkorp for a comment on the prospects of the patent.Read the interview with Cyxone's CEO Carl-Magnus Högerkorp at biostock.se: https://www.biostock.se/en/2023/04/cyxones-ceo-comments-on-the-us-patent-notice/ This is a press release from BioStock - Connecting Innovation & Capital. https:/

    Cyxone receives Notice of Allowance from the US Patent Office for the protection of Rabeximod compound

    Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the US patent application 17/891,462 entitled Rabeximod Compounds. The application covers the protection of salt forms of the compound Rabeximod which is being developed as treatment for moderate to severe rheumatoid arthritis.The notice of allowance is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent.

    Notice of extraordinary general meeting in Cyxone AB

    The English text is an unofficial translation. In case of any discrepancies between the Swedish language version of this document and the English translation, the Swedish language version shall prevail.The shareholders in Cyxone AB, Reg. No. 559020-5471 (“Cyxone”), are hereby invited to an extraordinary general meeting on Tuesday 18 April 2023 at 11.00 CEST, at the compa-ny’s office, Hyllie Boulevard 34 in Malmö, Sweden. Right to participate and notification Shareholders wishing to attend the annual general meeting must: · be registered in the company’s share register kept by

    Breakthrough in plant-based production of Cyxone’s T20K

    Cyxone (publ), a biotech company in autoimmune diseases, is developing T20K which acts to stop or slow down the progression of Multiple Sclerosis (MS). Researchers at the well renowned Center of Excellence for Innovations in Peptide and Protein Science, Australia have demonstrated a breakthrough in plant-based production of Cyxone’s T20K.The research findings means that sustainable, large scale and cost-effective production of cyclotide-based pharmaceuticals such as T20K, are now within reach.Since cyclotides are gene-encoded plant peptides, Professor David Craik and his team at University

    Cyxone makes significant progress in the manufacturing process for Rabeximod

    Cyxone (publ), a biotech company in autoimmune diseases, has in collaboration with its contract development and manufacturing organization (CDMO) managed to significantly streamline part of the manufacturing process of the drug candidate Rabeximod, which is under development for the treatment of rheumatoid arthritis (RA).As part of the continued development of Rabeximod, Cyxone is now, in collaboration with its CDMO, working on the development of creating a scalable manufacturing process for the late development phases as well as the commercialization of Rabeximod. Rabeximod is produced by

    Cyxone receive ethical and regulatory approval from Georgia to conduct clinical Phase 2b study in RA

    Cyxone (publ), a biotech company in autoimmune diseases, have received approvals from the Medical Product Agency (LEPL regulation Agency for Medical and Pharmaceutical Activities) and local Ethics Committees in Georgia to conduct a clinical Phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA).APPRAIS is a multicenter, randomised, double-blinded, placebo-controlled clinical study where patients with moderate to severe RA, who have previously been treated with methotrexate with inadequate response, will be treated with

    Cyxone advances the patent portfolio for Rabeximod

    Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that national phase filings have been completed in a large number of relevant markets for four of its pending PCT applications directed to clinically applicable forms and formulations of Rabeximod, as well as their medical use, potentially conferring patent protection until 2041.In November 2020 Cyxone reported the filing of five new patent applications though the international patent cooperation treaty (PCT) in order to strengthen the intellectual property protection for Rabeximod. Cyxone today reports the

    BioStock Studio: Cyxone's CEO on the current state and the pipeline

    Malmö-based biotech company Cyxone develops new therapies for the treatment of autoimmune diseases, such as rheumatoid arthritis with the phase IIb candidate Rabeximod and multiple sclerosis with drug candidate T20K. Carl-Magnus Högerkorp, recently appointed permanent CEO of Cyxone, visited BioStock's studio to tell us more about the current state and the prospects of the pipeline.Watch the interview with Cyxone's  CEO Carl-Magnus Högerkorp in the link below. https://www.biostock.se/en/2022/12/cyxones-ceo-on-the-current-state-and-the-pipeline/

    Cyxone appoints Carl-Magnus Högerkorp as permanent CEO

    Cyxone (publ), a biotech company in autoimmune diseases, has appointed Carl-Magnus Högerkorp as permanent CEO. Carl-Magnus Högerkorp has had the role of acting CEO since June 20, 2022.In Cyxone's continued work to strengthen and develop the company, the board decided to appoint Carl-Magnus as permanent CEO. Carl-Magnus has been an important part of the company since he started as the COO and has been a driving factor in the value-creating of the projects. Before Carl-Magnus started at Cyxone in 2021, he held several leading roles in various biotech companies in Lund. He worked as the CSO at

    Cyxone receive ethical and regulatory approval from Hungary to start clinical Phase 2b study in RA

    Cyxone (publ), a biotech company in autoimmune diseases, have received approval from the Hungarian Central Ethics Committee and the Medical Product Agency - National Institute of Pharmacy and Nutrition (OGYEI) to start a clinical Phase 2b study - APPRAIS - with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA).APPRAIS is a multicenter, randomised, double-blinded, placebo-controlled clinical study where patients with moderate to severe RA, who have previously been treated with methotrexate with inadequate response, will be treated with

    Nomination committee appointed for Cyxone Annual General Meeting 2023

    Cyxone AB (publ) hereby announces that the members of the nomination committee have been appointed ahead of the 2023 AGM. The nomination committee has been appointed in accordance with the guidelines laid down at the 2022 AGMThe nomination committee shall consist of four members, one representing each of the three largest shareholders along with the chairman of the board, in accordance with the principles adopted during the annual general meeting held on Monday, May 16, 2022. The nomination committee consists of: · Ivar Nordqvist · Göran Ofsén · Bert Junno, chairman of the

    BioStock: Cyxone reports Q3 and presents T20K

    Malmö-based Cyxone recently published its report for the third quarter, which testifies that the company is focusing on the phase IIb study with Rabeximod in rheumatoid arthritis. At the same time as the release of the report, the latest advances in the T20K program were presented at a scientific conference in the Netherlands. BioStock contacted acting CEO Carl-Magnus Högerkorp for an update.Read the full article at biostock.se: https://www.biostock.se/en/2022/11/cyxone-reports-q3-and-presents-t20k/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.

    Cyxone presents T20K program at the ECTRIMS conference

    Cyxone presents the latest results on the T20K project at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Amsterdam.Cyxone is together with its research collaboration partners at the Medical University of Vienna (MUV) investigating T20K for multiple sclerosis in preclinical research models. Recent discoveries have unveiled that T20K acts as a novel modulator of the k-opioid receptor (KOR). New data from therapeutic preclinical models demonstrated that a combination of T20K and a KOR drug show encouraging positive results: disease

    BioStock Studio: Cyxone on the phase IIb study

    In September, biotech company Cyxone was approved by Polish authorities to start a phase IIb trial with drug candidate Rabeximod in rheumatoid arthritis. The ambition is to develop a safe treatment with a new mechanism of action in an area of significant medical need. This is a milestone for Cyxone which also will conduct the study in additional countries. Carl-Magnus Högerkorp, acting CEO, visited BioStock's studio and talked about the approval and the trial.Watch the interview with Cyxone's  acting CEO Carl-Magnus Högerkorp at biostock.se: https://

    BioStock Investor Meeting: Interview with Cyxone

    Cyxone’s interim CEO Carl-Magnus Högerkorp was interviewed by BioStock after his presentation at the BioStock Investor Meeting. In the interview, Högerkorp tells us more about the upcoming phase II study with the company’s leading candidate Rabeximod, and answers the question of where the company expects to be in a year.See the full interview at biostock.se:https://www.biostock.se/en/2022/09/biostock-investor-meeting-interview-with-cyxone/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media